Crown Reserve Acquisition Corp. I Rights
CRACR
NASDAQ Global Market0.15
USD
+0.03
- -
CIK
0002070887
ISIN
KYG2574F1274
CUSIP
G2574F127
Return %
Stock
S&P500
1Y
-25.00
26.53
3Y
-25.00
76.60
5Y
-25.00
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Prashant Patel
- Sector
- Financial Services
- Industry
- Asset Management
- Address
- Conyers Trust Company (Cayman) Limited, PO Box 2681 Grand Cayman Cayman Islands KY1-1111
- IPO Date
- Dec 9, 2025
- CIK
- 0002070887
- Website
- leverageshares.com
- Similar Companies
- Business
- Crown Reserve Acquisition Corp. I is a blank check company, also known as a special purpose acquisition company (SPAC), incorporated in the Cayman Islands whose principal business activity is to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The company focuses its search for a target primarily in the pharmaceutical, medical technology, medical equipment and healthcare IT industries, though it may pursue opportunities in any business, industry or stage of corporate evolution. It offers investors units comprising Class A ordinary shares, redeemable warrants (one-half per unit, exercisable at $11.50 per whole warrant) and rights (entitling holders to one-fifth of one Class A ordinary share upon consummation of an initial business combination); separated securities trade under the symbols CRAC, CRACW and CRACR on the Nasdaq Global Market. Crown Reserve Acquisition Corp. I was incorporated in 2025 and maintains its principal executive offices at Conyers Trust Company (Cayman) Limited, PO Box 2681, Grand Cayman KY1-1111, Cayman Islands. In November 2025, the company successfully completed its initial public offering, raising $172.5 million through the sale of 17.25 million units at $10.00 per unit, underwritten by Polaris Advisory Partners LLC (a division of Kingswood Capital Partners LLC), with proceeds deposited into a trust account. On December 3, 2025, it announced the commencement of separate trading of its Class A ordinary shares, warrants and rights on or about December 9, 2025. The company is led by Chairman and Chief Executive Officer Prashant Patel, a healthcare entrepreneur and registered pharmacist, and Chief Financial Officer Eric Sherb, with no current employees or subsidiaries.